Klingel, Reinhard

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization

Roeseler, E., Julius, U., Heigl, F., Spitthoever, R., Heutling, D., Breitenberger, P., Leebmann, J., Lehmacher, W., Kamstrup, P. R., Nordestgaard, B. G., et al. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 227

Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels

Scientific Board of GLAR for the German Apheresis Working Group, Schettler, V. J. J., Neumann, C. L., Peter, C., Zimmermann, T., Julius, U., Hohenstein, B., Roeseler, E., Heigl, F., Grützmacher, P., et al. (2019) · Clinical Research in Cardiology Supplements

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 37